The EGF receptor (EGFR) tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib, represent essential therapeutical weapons for the treatment of patients with advanced non-small-cell lung cancer (NSCLC). Their clinical efficacy has been clearly established following characterization of their appropriate molecular target, which has allowed us to retrospectively distinguish between responding versus nonresponding patients in the context of the preliminary development conducted in an ‘unselected’ population.
Predictors of outcome for EGFR‑mutant non-small-cell lung cancer treated with first-line tyrosine kinase inhibitors.
Pilotto S.;Bria E.
2013-01-01
Abstract
The EGF receptor (EGFR) tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib, represent essential therapeutical weapons for the treatment of patients with advanced non-small-cell lung cancer (NSCLC). Their clinical efficacy has been clearly established following characterization of their appropriate molecular target, which has allowed us to retrospectively distinguish between responding versus nonresponding patients in the context of the preliminary development conducted in an ‘unselected’ population.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.